Preda CM, et al. - Because recent studies have suggested a higher rate of recurrence of hepatocellular carcinoma (HCC) in patients with a history of HCC and hepatitis C virus (HCV), a worldwide health problem that affects approximately 71 million people, -associated cirrhosis treated with direct-acting antiviral (DAA) agents. In this prospective analysis, researchers evaluated the rate of recurrence of HCC in patients with a history of treated HCC receiving ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin (OBV/PTV/r+DSV+RBV), as no consistent data from Eastern Europe have been published to date. The study sample consisted of 24 subjects with HCV-associated cirrhosis and treated HCC who received ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for 12 weeks. Data reported that the sustained virological response rate per protocol was 21/24 (87.5%). In patients with treated HCV-associated HCC, DAA therapy significantly decreased the recurrence rate of HCC and improved survival without recurrence.